Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
RC RCUS Arcus Biosciences, Inc. FY ended Feb 19, 2026 | $29.21 | $3.72B | $3.29B | $247.00M | -$345.00M | -$353.00M | -8.88x | 15.06x | — |
RP RPTX Repare Therapeutics Inc. FY ended Feb 21, 2025 | — | — | — | — | -$78.95M | -$84.69M | — | — | — |
ID IDYA IDEAYA Biosciences, Inc. FY ended Feb 13, 2026 | $40.11 | $3.87B | $3.30B | $218.71M | -$113.67M | -$113.70M | -31.34x | 17.70x | — |
MR MRSN Mersana Therapeutics, Inc. FY ended Feb 26, 2025 | — | — | — | $40.50M | -$63.10M | -$69.19M | — | — | — |
EX EXEL EXELIXIS, INC. FY ended Feb 02, 2026 | $54.45 | $13.49B | $12.83B | $2.32B | $975.59M | $782.57M | 19.59x | 5.82x | 12.88x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 13.46x | 1/5 | -$1.86B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 12.86x | 3/5 | $866.84M | $12.09 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -6.88x | 3/5 | $942.43M | $13.15 | Peer averages are not economically meaningful for this method. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
RC RCUS Arcus Biosciences, Inc. FY ended Feb 19, 2026 | $29.21 | $3.72B | $3.29B | $247.00M | -$345.00M | -$353.00M | -8.88x | 15.06x | — |
RP RPTX Repare Therapeutics Inc. FY ended Feb 21, 2025 | — | — | — | — | -$78.95M | -$84.69M | — | — | — |
ID IDYA IDEAYA Biosciences, Inc. FY ended Feb 13, 2026 | $40.11 | $3.87B | $3.30B | $218.71M | -$113.67M | -$113.70M | -31.34x | 17.70x | — |
MR MRSN Mersana Therapeutics, Inc. FY ended Feb 26, 2025 | — | — | — | $40.50M | -$63.10M | -$69.19M | — | — | — |
EX EXEL EXELIXIS, INC. FY ended Feb 02, 2026 | $54.45 | $13.49B | $12.83B | $2.32B | $975.59M | $782.57M | 19.59x | 5.82x | 12.88x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 13.46x | 1/5 | -$1.86B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 12.86x | 3/5 | $866.84M | $12.09 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -6.88x | 3/5 | $942.43M | $13.15 | Peer averages are not economically meaningful for this method. |
